NeuroSense Stock Soars 10.33% on ALS Treatment Commercialization Plans

On June 11, 2025, NeuroSense's stock surged by 10.33% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

NeuroSense Therapeutics has announced plans to file for early commercialization of its ALS treatment in Canada. This move is expected to accelerate the availability of the treatment, potentially boosting the company's market position and investor confidence.

In an interview, the company's CEO highlighted the potential impact of the US-China trade deal on the rare earth magnets market. While this topic is broader in scope, it underscores the strategic importance of NeuroSense's operations in the global market, which could indirectly influence its stock performance.